BiotechTube

bremelanotide

Phase 2Completed
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Female Sexual Arousal Disorder

Conditions

Female Sexual Arousal Disorder, Hypoactive Sexual Desire Disorder

Trial Timeline

Jun 1, 2011 → Sep 1, 2012

NCT ID
NCT01382719

About bremelanotide

bremelanotide is a phase 2 stage product being developed by Palatin Technologies for Female Sexual Arousal Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT01382719. Target conditions include Female Sexual Arousal Disorder, Hypoactive Sexual Desire Disorder.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (2)

NCT IDPhaseStatus
NCT02333071Phase 3Completed
NCT01382719Phase 2Completed

Competing Products

20 competing products in Female Sexual Arousal Disorder

See all competitors
ProductCompanyStageHype Score
Fulvestrant + AbemaciclibEli LillyPhase 2
52
Gemcitabine + liposomal doxorubicinEli LillyPhase 3
77
ASP3325 + PlaceboAstellas PharmaPhase 1
33
EnsitrelvirShionogiPhase 1
33
Eribulin Injection [Halaven] + Paclitaxel injectionEisaiApproved
85
Gemcitabine + Paclitaxel + CarboplatinEli LillyPhase 3
77
Abemaciclib 50 MG; 150mg 1-0-1 per osEli LillyPhase 3
77
Abemaciclib, durvalumab and aromatase inhibitorEli LillyPhase 1
33
norelgestromin/ethinyl estradiol (NGMN/EE) transdermal contraceptive system.Johnson & JohnsonPhase 1
33
Norgestimate/Ehinyl Estradiol; Folic acid.Johnson & JohnsonPhase 1
33
SHR6390 + placeboJiangsu Hengrui MedicinePhase 3
77
SHR7280 tabletsJiangsu Hengrui MedicinePhase 2
52
SHR7280；Ganirelix Acetate Injection simulant + SHR7280 simulant； Ganirelix Acetate InjectionJiangsu Hengrui MedicinePhase 3
77
SHR3162Jiangsu Hengrui MedicinePhase 1
33
AZD3293 + PlaceboAstraZenecaPhase 1
33
Fulvestrant 500mg + Palbociclib 125mg + Goserelin 3.6 MG + PlacebosAstraZenecaPhase 3
77
AZD2516 + PlaceboAstraZenecaPhase 1
33
Durvalumab + TremelimumabAstraZenecaPhase 2
52
Dapagliflozin + Metformin + Dapagliflozin + MetforminAstraZenecaPhase 1
33
AZD4901 (oral) + Placebo to match AZD4901AstraZenecaPhase 2
52

Other Products from Palatin Technologies

Bremelanotide + PlaceboPhase 3
69
Vehicle Ophthalmic Solution + PL9643 Ophthalmic SolutionPhase 3
69
BremelanotidePhase 3
69
PL8177 Placebo + PL8177Phase 2
44
Bremelanotide + RAAS inhibition therapyPhase 2
44